{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:50:40Z","timestamp":1773283840127,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Medical conditions with effective therapies are usually managed with objective measurement and therapeutic targets. Parkinson\u2019s disease has effective therapies, but continuous objective measurement has only recently become available. This blinded, controlled study examined whether management of Parkinson\u2019s disease was improved when clinical assessment and therapeutic decisions were aided by objective measurement. The primary endpoint was improvement in the Movement Disorder Society-United Parkinson\u2019s Disease Rating Scale\u2019s (MDS-UPDRS) Total Score. In one arm, objective measurement assisted doctors to alter therapy over successive visits until objective measurement scores were in target. Patients in the other arm were conventionally assessed and therapies were changed until judged optimal. There were 75 subjects in the objective measurement arm and 79 in the arm with conventional assessment and treatment. There were statistically significant improvements in the moderate clinically meaningful range in the MDS-UPDRS Total, III, IV scales in the arm using objective measurement, but not in the conventionally treated arm. These findings show that global motor and non-motor disability is improved when management of Parkinson\u2019s disease is assisted by objective measurement.<\/jats:p>","DOI":"10.1038\/s41531-020-00136-9","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T11:07:06Z","timestamp":1605870426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A blinded, controlled trial of objective measurement in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Holly","family":"Woodrow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-2100","authenticated-orcid":false,"given":"Malcolm K.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chathurini V.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya E.","family":"Kotschet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Treat to Target Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arup","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Blaze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Charmley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Cruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Duma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blake","family":"Giarola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kimber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Lehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Mahant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salar","family":"McModie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiliang Melissa","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Tisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Winkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Wools","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"136_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3399\/bjgp09X420905","volume":"59","author":"DG Altman","year":"2009","unstructured":"Altman, D. G. Assessing new methods of clinical measurement. Br. J. Gen. Pract. 59, 399\u2013400 (2009).","journal-title":"Br. J. Gen. Pract."},{"key":"136_CR2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/mds.26673","volume":"31","author":"W Maetzler","year":"2016","unstructured":"Maetzler, W., Klucken, J. & Horne, M. A clinical view on the development of technology-based tools in managing Parkinson\u2019s disease. Mov. Disord. 31, 1263\u20131271 (2016).","journal-title":"Mov. Disord."},{"key":"136_CR3","unstructured":"Farzanehfar, P., Braybrook, M., Kotschet, K. & Horne, M. Objective measurement in clinical care of patients with parkinson\u2019s disease: an RCT using the PKG. In 20th International Congress of Parkinons\u2019 Disorders and Movement Disorders. Berlin, Germany (2016)."},{"key":"136_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-018-0046-4","volume":"4","author":"P Farzanehfar","year":"2018","unstructured":"Farzanehfar, P. et al. Objective measurement in routine care of people with Parkinson\u2019s disease improves outcomes. NPJ Parkinsons Dis. 4, 10 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"136_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman, L. M. et al. The clinically important difference on the unified Parkinson\u2019s disease rating scale. Arch. Neurol. 67, 64\u201370 (2010).","journal-title":"Arch. Neurol."},{"key":"136_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/mds.870130111","volume":"13","author":"O Rascol","year":"1998","unstructured":"Rascol, O. et al. Ropinirole in the treatment of early Parkinson\u2019s disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov. Disord. 13, 39\u201345 (1998).","journal-title":"Mov. Disord."},{"key":"136_CR7","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284, 1931\u20131938 (2000).","DOI":"10.1001\/jama.284.15.1931"},{"key":"136_CR8","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn, S. et al. Levodopa and the progression of Parkinson\u2019s disease. N. Engl. J. Med. 351, 2498\u20132508 (2004).","journal-title":"N. Engl. J. Med."},{"key":"136_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N. Engl. J. Med. 355, 896\u2013908 (2006).","journal-title":"N. Engl. J. Med."},{"key":"136_CR10","unstructured":"Horne, M., Kotschet, K. & Braybrook, M. Objective measurement in clinical care of patients with Parkinson\u2019s disease. Mov. Disord. 31, Poster 1964 (2016)."},{"key":"136_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JPD-2012-11071","volume":"2","author":"RI Griffiths","year":"2012","unstructured":"Griffiths, R. I. et al. Automated assessment of bradykinesia and dyskinesia in Parkinson\u2019s disease. J. Parkinsons Dis. 2, 47\u201355 (2012).","journal-title":"J. Parkinsons Dis."},{"key":"136_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/17434440.2017.1349608","volume":"14","author":"P Farzanehfar","year":"2017","unstructured":"Farzanehfar, P. & Horne, M. Evaluation of the Parkinson\u2019s KinetiGraph in monitoring and managing Parkinson\u2019s disease. Expert Rev. Med. Devices 14, 583\u2013591 (2017).","journal-title":"Expert Rev. Med. Devices"},{"key":"136_CR13","doi-asserted-by":"publisher","first-page":"A685","DOI":"10.1016\/j.jval.2015.09.2534","volume":"18","author":"M Horne","year":"2015","unstructured":"Horne, M., McGregor, S., Lynch, P. & Zoellner, Y. Objective data in Parkinson\u2019s disease therapy management\u2014a retrospective analysis of the Parkinson\u2019s Kinetigraph (Pkg) Database. Value Health. 18, A685 (2015).","journal-title":"Value Health."},{"key":"136_CR14","first-page":"16","volume":"1","author":"MK Horne","year":"2016","unstructured":"Horne, M. K., Kotschet, K. & McGregor, S. The clinical validation of objective measurement of movement in Parkinson\u2019s disease. Cent. Nerv. Sytem 1, 16\u201323 (2016).","journal-title":"Cent. Nerv. Sytem"},{"key":"136_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124522","volume":"10","author":"MK Horne","year":"2015","unstructured":"Horne, M. K., McGregor, S. & Bergquist, F. An objective fluctuation score for Parkinson\u2019s disease. PLoS ONE 10, e0124522 (2015).","journal-title":"PLoS ONE"},{"key":"136_CR16","doi-asserted-by":"publisher","unstructured":"Khodakarami, H., Farzanehfar, P. & Horne, M. The use of data from the parkinson\u2019s kinetigraph to identify potential candidates for device assisted therapies. Sensors (Basel) 19, https:\/\/doi.org\/10.3390\/s19102241 (2019).","DOI":"10.3390\/s19102241"},{"key":"136_CR17","doi-asserted-by":"publisher","unstructured":"Khodakarami, H. et al. Prediction of the Levodopa Challenge Test in Parkinson\u2019s Disease Using Data from a Wrist-Worn Sensor. Sensors (Basel) 19, https:\/\/doi.org\/10.3390\/s19235153 (2019).","DOI":"10.3390\/s19235153"},{"key":"136_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/ene.13015","volume":"23","author":"L Klingelhoefer","year":"2016","unstructured":"Klingelhoefer, L. et al. Night-time sleep in Parkinson\u2019s disease\u2014the potential use of Parkinson\u2019s KinetiGraph: a prospective comparative study. Eur. J. Neurol. 23, 1275\u20131288 (2016).","journal-title":"Eur. J. Neurol."},{"key":"136_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-017-0038-9","volume":"4","author":"S McGregor","year":"2018","unstructured":"McGregor, S. et al. The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson\u2019s disease. NPJ Parkinsons Dis. 4, 1 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"136_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.parkreldis.2014.02.011","volume":"20","author":"K Kotschet","year":"2014","unstructured":"Kotschet, K. et al. Daytime sleep in Parkinson\u2019s disease measured by episodes of immobility. Parkinsonism Relat. Disord. 20, 578\u2013583 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"136_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161559","volume":"11","author":"C Ossig","year":"2016","unstructured":"Ossig, C. et al. Correlation of quantitative motor state assessment using a kinetograph and patient diaries in advanced PD: data from an observational study. PLoS ONE 11, e0161559 (2016).","journal-title":"PLoS ONE"},{"key":"136_CR22","doi-asserted-by":"publisher","unstructured":"Braybrook, M. et al. An ambulatory tremor score for Parkinson\u2019s disease. J. Parkinson\u2019s Dis. https:\/\/doi.org\/10.3233\/JPD-160898 (2016).","DOI":"10.3233\/JPD-160898"},{"key":"136_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41531-018-0051-7","volume":"4","author":"P Odin","year":"2018","unstructured":"Odin, P. et al. Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson\u2019s disease. NPJ Parkinsons Dis. 4, 14 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"136_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/14737175.2018.1503948","volume":"18","author":"R Pahwa","year":"2018","unstructured":"Pahwa, R. et al. Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson\u2019s disease: recommendations from an expert panel. Expert Rev. Neurother. 18, 669\u2013680 (2018).","journal-title":"Expert Rev. Neurother."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00136-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00136-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00136-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T03:04:10Z","timestamp":1670295850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00136-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1038\/s41531-020-00136-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K.H. is the inventor of the P.K.G. and is a paid consultant to G.K.C. (the manufacturer of the P.K.G.) to develop new products for the P.K.G. M.K.H. did not receive any personal or laboratory funding to undertake this study. The study, sponsored by the Florey Institute of Neurosciences and Mental Health, was investigator initiated, designed and led. The study was administered and conducted by staff from the Florey, and G.K.C. (the manufacturer of the P.K.G.) had no influence on the conduct of this study or the writing of this manuscript. It did not provide funding other than in kind gift of the P.K.G. loggers. K.E.K. and M.K.H. have financial interest in G.K.C. H.W. and C.V.F. were funded from the grants to undertake this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}